

Rexulti (brexiprazole)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION		
LAST NAME:		FIRST NAME:
PHONE NUMBER:		DATE OF BIRTH:
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

☐ MALE ☐ FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](https://primetherapeutics.com/nopp)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.

Rexulti (brexiprazole)

Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Major depressive disorder(MDD) <input type="checkbox"/> Schizophrenia <input type="checkbox"/> Agitation associated with dementia due to Alzheimer's disease		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
<p><u>Major depressive disorder:</u> Does the patient have a diagnosis of major depressive disorder? <input type="checkbox"/> Yes <input type="checkbox"/> No Has patient had a diagnosis of major depressive disorder for at least 24months? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Has patient been treated for their major depressive disorder with a mininum of 4 different antidepressants for a minimum of 6 weeks per drug regimen? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Is patient unable to reach a 50% improvement in their depressive symptoms? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Does patient have another psychiatric diagnosis? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Does patient have an eating disorder? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Does patient have substance use disorder? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Will patient continue to use Rexulti(brexiprazole) in combination with another antidepressant? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i></p> <p><u>Schizophrenia:</u> Does the patient have a diagnosis of schizophrenia? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient previously tried Abilify (aripiprazole)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i></p> <p><u>Agitation associated with dementia due to Alzheimer's disease:</u> Does patient have a diagnosis of Alzheimer's disease? <input type="checkbox"/> Yes <input type="checkbox"/> No Does patient have a Mini-Mental State Exam score of 5 to 22, inclusive, prior to starting Rexulti(brexiprazole)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i> Has patient had symptoms of agitation for at least 2 weeks prior to starting Rexulti(brexiprazole)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please submit documentation.</i></p>		

Rexulti (brexpiprazole)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Does patient have a score of greater than or equal to 4 on the agitation/aggression item of the Neuropsychiatric Inventory-Nursing Home Scale(documentation required)? ☐ Yes ☐ No *Please submit documentation.*

Have all other causes for the patient's agitation been ruled out, such as pain, infection, polypharmacy? ☐ Yes ☐ No

Does patient have a history of bipolar-disorder or a psychotic disorder not related to dementia? ☐ Yes ☐ No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201

P.O. Box 64811

St. Paul, MN 55164-0811